These results indicate that inflammasome-induced release of IL-1β by TAMs may contribute to tumor growth of HCC cells, a mechanism that would be reduced by treatment with an inflammasome inhibitor such as MCC950 (Figure 5B). Here, IL1B is linked to hepatocellular carcinoma.